Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Coeptis Therapeutics Holdings, Inc. before investing.

In this article, we go over a few key elements for understanding Coeptis Therapeutics Holdings, Inc.’s stock price such as:

• Coeptis Therapeutics Holdings, Inc.’s current stock price and volume
• Why Coeptis Therapeutics Holdings, Inc.’s stock price changed recently
• Upgrades and downgrades for COEP from analysts
• COEP’s stock price momentum as measured by its relative strength

About Coeptis Therapeutics Holdings, Inc. (COEP)

Before we jump into Coeptis Therapeutics Holdings, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Coeptis Therapeutics Holdings, Inc., together with its subsidiaries, operates as a biopharmaceutical company. The company is developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio and rights are licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform; and DVX201, a clinical-stage, natural killer cell therapy technology. Its product pipeline consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy; and SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological and solid tumors. In addition, the company offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson’s Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

Want to learn more about Coeptis Therapeutics Holdings, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Coeptis Therapeutics Holdings, Inc..

Coeptis Therapeutics Holdings, Inc.’s Stock Price as of Market Close

As of December 10, 2025, 3:58 PM, CST, Coeptis Therapeutics Holdings, Inc.’s stock price was $15.305.

Coeptis Therapeutics Holdings, Inc. is down 1.95% from its previous closing price of $15.610.

During the last market session, Coeptis Therapeutics Holdings, Inc.’s stock traded between $15.000 and $16.060. Currently, there are approximately 4.75 million shares outstanding for Coeptis Therapeutics Holdings, Inc..

Coeptis Therapeutics Holdings, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Coeptis Therapeutics Holdings, Inc. Stock Price History

Coeptis Therapeutics Holdings, Inc.’s (COEP) price is currently down 18.29% so far this month.

During the month of December, Coeptis Therapeutics Holdings, Inc.’s stock price has reached a high of $18.890 and a low of $15.000.

Over the last year, Coeptis Therapeutics Holdings, Inc. has hit prices as high as $21.410 and as low as $2.310. Year to date, Coeptis Therapeutics Holdings, Inc.’s stock is up 178.27%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Coeptis Therapeutics Holdings, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of December 09, 2025, there were analysts who downgraded Coeptis Therapeutics Holdings, Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Coeptis Therapeutics Holdings, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Coeptis Therapeutics Holdings, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Coeptis Therapeutics Holdings, Inc.’s current valuation based on AAII’s Value Grade is a D, which means it is considered to be Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Coeptis Therapeutics Holdings, Inc. (COEP) by visiting AAII Stock Evaluator.

Relative Price Strength of Coeptis Therapeutics Holdings, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of December 09, 2025, Coeptis Therapeutics Holdings, Inc. has a weighted four-quarter relative price strength of 49.06%, which translates to a Momentum Score of 98 and is considered to be Very Strong.

Want to learn more about how Coeptis Therapeutics Holdings, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Coeptis Therapeutics Holdings, Inc. Stock Price: Bottom Line

As of December 10, 2025, Coeptis Therapeutics Holdings, Inc.’s stock price is $15.305, which is down 1.95% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Coeptis Therapeutics Holdings, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.